pocketful logo
Kopran Ltd logo

Kopran Ltd

NSE: KOPRAN BSE: 524280

₹131.83

(-1.18%)

Tue, 03 Mar 2026, 09:36 am

mtf coin illustrationMTF 5x

Company History

1958

  • The Company was incorporated as a private limited company under the name Kopran Chemical Company Pvt. Ltd

1972

  • The Company's management was acquired by Chemo Pharma Laboratories Ltd

1984

  • The Company was converted into a public limited company

1985

  • The Company launched a special purpose antibiotic bulk drug Cephlaxin Monohydrate and an anti-TB formulation Rifampicin
  • The Company integrated backwards into manufacture of 6APA a raw material required for bulk drug production

1990

  • The Company changed its name to Kopran Limited
  • The Company manufactured medical formulations with production of bulk drugs and drug intermediates being introduced in 1983

1992

  • The Company launched a new concept in the treatment of ulcers-Omeprazole under the brand name of LOKIT
  • The company issued equity shares of Rs 10/- each at a premium of Rs 80/- per share aggregating Rs 1440 lakhs
  • The company was amongst the promoters of Pharmacuetical Business Group (India) Ltd

1993

  • The company won the second award for export performance for the year 1991-92 from CHEMEXCIL

1994

  • The Company promoted two subsidiaries, viz., Kopran International in United Kingdom and Kopran (H.K.) based in HongKong
  • The Company received the Indian Drug Manufacturers Association's QUALITY EXCELLENCE AWARD 1993 and the EUROPE QUALITY AWARD - 1993

1995

  • The Company issued Bonus Equity Shares in the ratio of 1:2

1996

  • The Company received the TRISHUL Award under the Large Scale Manufacturer category from CHEMEXCIL
  • The Company launched various new products like TRASIC, SOLOFLOX, ZIMAT

1997

  • The company launched various new products like AZ-1 Caps, Klodip Tabs, Moclox Kid Tabs, Amyn Kid Tabs, Tini-NF, Amyn Caps, Amyn Dry Syrup
  • The company entered into a joint venture with M/s. Industrial Promotion Services Ltd
  • Kopran Limited won the IDMA Award for Quality Excellence for the fourth time in a row
  • Kopran Ltd entered into a memorandum of understanding with Pharmacare Ltd to set up a 50:50 joint venture project

1998

  • Kopran Drugs Ltd and Synpac Pharmaceuticals Ltd entered into a strategic alliance
  • Kopran Ltd set up a dedicated marketing division under Kresp

1999

  • Kopran Drugs Ltd set up under a strategic alliance with the UK-based Synpac Pharmaceuticals
  • Kopran Ltd set up a pharmaceutical company in Dubai in association with Dubai Investments PJSC
  • Kopran has a state-of-the-art formulations plant at Sarvoli

2000

  • Kopran Pharmaceuticals introduced the American Dreams range of fine perfumes in India
  • Kopran Pharmaceuticals launched a range of digestive tablets branded Yum Tum
  • KResp launched a new aerosol holding device called Vent-Mate
  • Kopran Ltd tied up with E Merck India for marketing Atorvastain
  • Kopran Ltd fixed the swap ratio for the merger of group company Kopran Pharmaceuticals with it at 17:1

2001

  • The Company tied up with E Merck Ltd for a co-marketing arrangement for a new antiinflammatory oranalgestic drug Rofecoxib
  • Kopran Ltd launched Dr Smyle Prickly Heat Powder
  • Kopran Ltd sold the marketing rights for its anti-hypertensive drug Aten to Zydus Cadila

2002

  • Mr Humayun Dhanrajgir resigned from Directorship

2003

  • Kopran received approval from the patent office of the US for its new chemical entity (NCE), KNC-6
  • Kopran received approval for restructuring its high cost debts from the Corporate Debt Restructuring (CDR) Cell
  • HSBC Financial Services acquired a 6.06 per cent stake in Kopran Pharmaceuticals
  • Kopran received approval from EDQM for its API facility at Mahad

2004

  • The Stock Exchange Ahmedabad delisted the shares of the Company
  • Merrill Lynch Capital Markets Espana SA SV acquired an 8.49 per cent stake in Kopran
  • Mr. Tapan Ray resigned as Managing Director of the company

2005

  • The Company appointed Mr.H.P.Vyas as Company Secretary
  • The Company entered into a Strategic Alliance with Merck Specialities Pvt Ltd

2006

  • The company signed a distribution pact with Mumbai-based Manish Pharma for its complete range of over the counter (OTC) products

2011

  • The company appointed Mr. Abhinav Mathur as a Company Secretary & Compliance Officer

2013

  • Kopran Ltd. launched a new brand SPARKLE in the FMCG category

2018

  • Kopran Research Laboratories Limited, a wholly owned subsidiary of the Company purchased API facility at Panoli, Gujarat

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

pocketful logo

2022-25 Pocketful. All rights reserved, Built with in India

Version -5.76

app image 1app image 2

Stocks:

AllABCDEFGHIJKLMNOPQRSTUVWXYZ

Explore

Calculatorsfooter arrow down icon
Popular Calculatorsfooter arrow down icon
Group Stocksfooter arrow down icon

Others:

NSEBSECDSLNSDLSEBIMCXMSEINCDEXNSE IFSCINDIA INXAccount Closure FormDP Investor CharterBroker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800